Patent Pharma Damages After an At-Risk Launch: A Real World Approach

July 17, 2018


Jake M. Holdreith


Managing Partner, Minneapolis Office
Member of Executive Board

Proving damages in patent pharmaceutical cases can be challenging, as the Georgia Pacific elements are not clearly adapted for pharma markets. Learn from two experienced practitioners how to successfully prove reasonable royalties in pharma cases after an at-risk launch. Join JakeHoldreith, Christopher Pinahs, and Mark Robbins for a lively discussion of patent damages. 

Jake M. Holdreith is a trial lawyer who leads the Hatch-Waxman practice at Robins Kaplan LLP. Christopher A. Pinahs is an Associate at Robins Kaplan LLP. Mark Robbins is a pharmaceutical attorney and consultant at Kodiak Strategic Consultants who frequently testifies as an expert witness on pharmaceutical antitrust and patent litigation, including reasonable royalty rate determinations. He has over 30 years of experience in leadership positions in legal, regulatory, and scientific roles at leading pharmaceutical companies and extensive experience in pharma licensing.

Related Publications

March 22, 2024
‘In re Cellect’:
Derrick Carman - New York Law Journal
December 28, 2023
Data Shows Most SEP Holders Send Pre-Suit Demand Letters - For Good Reason
Aaron Fahrenkrog, Benjamen Linden, Navin Ramalingam - IAM
July 7, 2023
September 13, 2022
Patent Value: Scoring Patents Using Characteristics Of Patents In Litigation
Christopher K. Larus, Miles A. Finn, Congnan Zhan, Joseph (Yu) Chen, and Shelley Gilliss - les Nouvelles
August 25, 2022